278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiot... von Campian, J.L., Butt, O., Huang, J., Luo, J., Tao, Y., Strowd, R., Hissim, D., Kizilbash, S.H., Abraham, C., Ansstas, G., Johanns, T., Kim, A., Ciorba, M., Chheda, M.

Volltext

Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor von Kizilbash, S.H., El-Khoueiry, A., Lerner, R.E., Ma, P.C., Almubarak, M., Mody, K., Burkard, M.E., Guarino, M., Jenab-Wolcott, J., Sankar, N., Choy, G., Espiritu, L., Zhang, X., Luria, A., Benedetti, F., Dees, E.C.

Volltext

PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recurrent Glioblastoma von Shih, K.C., Patel, M.R., Butowski, N., Falchook, G.S., Kizilbash, S.H., Bacha, J.A., Brown, D.M., Steino, A., Schwartz, R., Kanekal, S., Lopez, L.M., Burris, H.A.

Volltext

An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence von Riviere-Cazaux, C, Carlstrom, L.P, Neth, B.J, Olson, I.E, Rajani, K, Rahman, M, Ikram, S, Mansour, M.A, Mukherjee, B, Warrington, A.E, Short, S.C, von Zglinicki, T, Brown, D.A, Burma, S, Tchkonia, T, Schafer, M.J, Baker, D.J, Kizilbash, S.H, Kirkland, J.L, Burns, T.C

Volltext bestellen